010-58156160-822
EN
010-58156160-822
EN
To facilitate the internationalization of Chinese innovative brands by promoting and implementing the national Innovation Driven Development Strategy, enhancing the core competitiveness of innovative technology and advancing the process of strengthening the nation by technology and pharmaceutical development, China Pharmaceutical Innovation and Research Development Association (PhIRDA) and Suzhou Industrial Park have reached a consensus on co-hosting the “Dushu Lake Prize” Selection Activities of China Pharmaceutical Innovation Brand (herein after referred to as the Selection Activities) in 2018. Both sides will join hands to make the Selection Activities a fair, just, and open session.
The Selection Activities adopts the mechanism of expert recommendation. Any applications from enterprises shall not be taken into consideration. The selection will follow the peer review system of international innovation standards and scientific awards to set the awards for the most innovative drugs, figures (Chinese scientists) and financial institutions.
Kaixian Chen
Academician of Chinese Academy of Sciences (CAS), Researcher, Director of Academic Degree Committee of Shanghai Institute of Materia Medica (SIMM), CAS
Jiang Jiandong
Director of Institute of Materia Medica (IMM), Chinese Academy of Medical Sciences (CAMS)
Zhang Boli
Academician of CAE, Former President of China Academy of Chinese Medical Sciences, President of Tianjin University of Traditional Chinese Medicine
Jiang Hualiang
Academician of CAS, Researcher of SIMM, CAS
Zhao Kai
Academician of CAE, Researcher of National Vaccine and Serum Institute
Ding Jian
Academician of CAE, Academician of the World Academy of Sciences
Wang Guangji
Academician of CAE, Chairman of the Academic Committee & Director of Key Laboratory,China Pharmaceutical University
Ge Junbo
Academician of CAS, Dean of Institutes of Biomedical Sciences, Fudan University, Director of Cardiology Department of Zhongshan Hospital, Fudan University
Wei Yuquan
Academician of CAS, Professor of National Key Laboratory of Biotherapy, Sichuan University
Li Lin
Academician of CAS, President of Shanghai Institutes for Biological Sciences, CAS
Chen Jianfeng
Academician of CAE, Vice President of Beijing University of Chemical Technology
Yue Jianmin
Academician of CAS, Researcher of SIMM, CAS
Li Zhaoshen
Academician of CAE, Director of Department of Gastroenterology of Changhai Hospital of Shanghai
Ye Yuru
Academician of CAS, Foreign Academician of National Academy of Sciences, United States
Wang Hongyang
Academician of CAE, Director of The National Center for Science in Hepatocellular Carcinoma
Yu Jinming
Academician of CAE, Honorary President/Principal of Shandong First Medical University & Shandong Academy of Medical Sciences
Ning Guang
Academician of CAE, Vice President of Ruijin Hospital, Shanghai Jiaotong University
Wang Junzhi
Academician of CAE, Chief Expert for Biological Product Testing in National Institutes for Food and Drug Control (NIFDC)
Lai Maode
President of China Pharmaceutical University
Wu Chunfu
Professor of Shenyang Pharmaceutical University
Wu Xiaoming
Professor & Former President of China Pharmaceutical University
Chen Xiaoguang
Director of Department of Pharmacology of IMM, CAMS
Ji Jiafu
President of Beijing Cancer Hospital
Wang Yongjun
Executive Deputy Dean of Beijing Tiantan Hospital, Capital Medical University
Shi Yuankai
Deputy Director of National Cancer Center, Vice President of Cancer Hospital, CAMS
Zhang Shuyang
President of Peking Union Medical College Hospital, vice president of China Alliance for Rare Diseases
Wu Yilong
Tenured Professor & Director of Guangdong General Hospital (GGH)
Zhou Zhiguang
President of the Second Xiangya Hospital of Central South University
Qin Shukui
Director of Cancer Center of General Hospital of Eastern Theater Command
Huo Yong
Director of Department of Cardiology and Heart Center, Peking University First Hospital
Ma Jun
Executive Vice President of Sun Yat-Sen University Cancer Center
He Ruyi
Chief Scientist at SDIC, Former Chief Scientist at Center for Drug Evaluation of NMPA
Hou Jian
Director of Department of Hematology of Renji Hospital of Shanghai Jiaotong University School of Medicine
Li Wenbin
Director of Department of Neuro-Oncology of Beijing Tiantan Hospital, Capital Medical University
Li Jia
Director of SIMM, CAS, Director of State Key Laboratory of Drug Research
Liang Jun
Vice President, Director of Cancer Center of Peking University International Hospital
Ma Jun
Director of Harbin Institute of Hematology
Hu Yi
Director of Oncology Department, Chinese PLA General Hospital
Wang Weiqing
Director of the Department of Endocrine and Metabolism of Ruijin Hospital
Shi Jin
DirectorDirector of Neurology Department of Air Force General Hospital, PLA
Zhang Shucai
ChiefDirector of the Oncology Medicine Department of Beijing Chest Hospital, Capital Medical University
Dong Qiang
Director of Department of Neurology of Huashan Hospital
Linghu Enqiang
Director of Department of Gastroenterology, Chinese PLA General Hospital
Li Jin
Director of Department of Oncology of Shanghai East Hospital, Tongji University
Zhong Wu
Director of National Engineering Research Center for the Emergency Drug
Zhu Xiaoxin
Researcher of Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences
Xuan Jianwei
Director of Medicine Economic Research Institute of School of Pharmaceutical Sciences, Sun Yat-Sen University
Shen Xinliang
Vice Chairman of the Committee of Genetic Engineering Drugs
Huang Jiaoti
Tenure Professor and Department Head of Duke University Medical Center
Song Wenru
Co-founder, President and Head of R&D of Kira Pharmaceuticals
Ren Jin
Director of Center for Drug Safety Evaluation and Research of SIMM, CAS
Wang Xinghe
Director of New Drug Clinical Trial Center of Beijing Shijitan Hospital, Capital Medical University
Cui Yimin
Director of Clinical Trial Center, Peking University First Hospital
Hu Xin
Director of Department of Pharmacy, Beijing Hospital
Wang Xiaoling
Director of Department of Pharmacy, Beijing Childrens Hospital, Capital Medical University
Li Kexin
Director of Beijing Hospital Clinical Trial Research Center (BJH-CTC)
Song Ruilin
Chairman of China Pharmaceutical Innovation and Research Development Association (PhIRDA)
Awards List
Sun Yan, Director of National GCP Center for Anticancer Agents, NCC，CAMS, Academician of Chinese Academy of Engineering
Awards List
LIU Yongjun, Global Research Head, Sanofi
Awards List
Roxadustat Capsule from Fibrogen (China) Medical Technology Development Co., Ltd.
Awards List
Yu Dechao, Chairman of the Board & President, Innovent Biologics (Suzhou) Co., Ltd.
Awards List
Hou Jian, Director of the Department of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine
Zhang Li, Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Awards List
Inactivated Poliomyelitis Vaccine Made From Sabin Strains (Vero cell); Oral Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell) from China National Biotech Corporation
Awards List
Protocol Designer: Ma Jun, Professor, Sun Yat-Sen University Cancer Center 'Gemcitabine combined with Cisplatin induction chemotherapy for nasopharyngeal carcinoma' Clinical Trial Protocol
Addressed by Song Ruilin, Chairman of PhIRDA
Addressed by Wu Qingwen, Member of the Standing Committee of CPC Suzhou Committee, Secretary of SIP Working Committee
Winner of Award for Medical Innovation Lifetime Achievement
Winner of Most Innovative Figure of Drug R&D Award (International Areas)
Winner of Most Innovative Figure of Drug R&D Award
Winner of Clinical Trial Protocol Design Award
